{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:10:58Z","timestamp":1791051058545,"version":"4.1.0"},"reference-count":147,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1016\/j.ctrv.2007.08.003","type":"journal-article","created":{"date-parts":[[2007,10,2]],"date-time":"2007-10-02T15:18:11Z","timestamp":1191338291000},"page":"710-728","source":"Crossref","is-referenced-by-count":30,"title":["Recent progress in the management of chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"33","author":[{"given":"Tadeusz","family":"Robak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2007.08.003_bib1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2354.2004.00489.x","article-title":"The clinical and epidemiological burden of chronic lymphocytic leukaemia","volume":"13","author":"Redaelli","year":"2004","journal-title":"Eur J Cancer Care"},{"key":"10.1016\/j.ctrv.2007.08.003_bib2","unstructured":"Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review 1975\u20132001. Bethesda, MD: National Cancer Institute 2001."},{"key":"10.1016\/j.ctrv.2007.08.003_bib3","unstructured":"Ries LAG, Eisner MP, Kosary CL, et al. Editors. SEER Cancer Statistics Review 1975\u20132001. Bethesda (MD); National Cancer Institute (online). Available from URL: htp:\/\/seer.cancer.gov\/csr\/1975.2000 [accessed 2005 November 18]."},{"key":"10.1016\/j.ctrv.2007.08.003_bib4","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJM200012143432410","article-title":"When and how to treat chronic lymphocytic leukemia","volume":"343","author":"Dighiero","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2007.08.003_bib5","first-page":"985","article-title":"Therapy of chronic lymphocytic leukemia with purine nucleoside analogues: Facts and controversies","volume":"22","author":"Robak","year":"2006","journal-title":"Drug Aging"},{"key":"10.1016\/j.ctrv.2007.08.003_bib6","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","article-title":"National Cancer Institute sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment","volume":"87","author":"Cheson","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2141.1990.tb07835.x","article-title":"Natural history of stage A chronic lymphocytic leukemia untreated patients","volume":"76","author":"French Cooperative Group on Chronic Lymphocytic Leukemia","year":"1990","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib8","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood.V78.4.895.895","article-title":"Progression and survival studies in early chronic lymphocytic leukemia","volume":"78","author":"Molica","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib9","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2007.08.003_bib10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib11","first-page":"391","article-title":"Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies","volume":"90","author":"Montiilo","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2007.08.003_bib12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/sj.thj.6200139","article-title":"Classical and new prognostic factors in chronic lymphocytic leukemia: where to now ?","volume":"3","author":"Montserrat","year":"2002","journal-title":"Hematol J"},{"key":"10.1016\/j.ctrv.2007.08.003_bib13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000205558","article-title":"Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia","volume":"81","author":"Di Giovanni","year":"1989","journal-title":"Acta Haematol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib14","first-page":"1732","article-title":"Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia","volume":"93","author":"Hallek","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib15","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib16","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated IgV(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib17","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2007.08.003_bib18","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.hoc.2004.04.003","article-title":"Molecular genetics and its clinical relevance","volume":"18","author":"Stilgenbauer","year":"2004","journal-title":"Hematol. Oncol Clin N Am"},{"key":"10.1016\/j.ctrv.2007.08.003_bib19","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1084\/jem.194.11.1639","article-title":"Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia","volume":"194","author":"Rosewald","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.ctrv.2007.08.003_bib20","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJMoa023143","article-title":"ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia","volume":"348","author":"Crespo","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2007.08.003_bib21","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2002-10-3306","article-title":"ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile","volume":"101","author":"Wiestner","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib22","first-page":"683","article-title":"ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in B-cell chronic lymphocytic leukaemia","volume":"17","author":"Rassenti","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib23","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/annonc\/mdj120","article-title":"The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia","volume":"17","author":"Hus","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib24","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/cyto.b.20131","article-title":"Clinical implications of ZAP-70 expression in chronic lymphocytic leukemia","volume":"708","author":"Bosch","year":"2006","journal-title":"Cytom B Clin Cytom"},{"key":"10.1016\/j.ctrv.2007.08.003_bib25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(03)15260-9","article-title":"ZAP-70 expression and prognosis in chronic lymphocytic leukemia","volume":"36","author":"Orchard","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2007.08.003_bib26","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/sj.leu.2402531","article-title":"Alkylating agents and nucleoside analogues in the treatment of B-cell chronic lymphocytic leukemia","volume":"16","author":"Robak","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2007.08.003_bib27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/10428190310001595704","article-title":"High dose chlorambucil in the treatment of lymphoid malignancies","volume":"45","author":"Nicolle","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2007.08.003_bib28","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/(SICI)1097-0142(19970601)79:11<2107::AID-CNCR7>3.0.CO;2-L","article-title":"High dose chlorambucil versus Binet\u2019s modified cyclophosphamide, doxorubicin, vincristine and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia: results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy. Vienna","volume":"79","author":"Jaksic","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2007.08.003_bib29","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199805213382104","article-title":"Chlorambucil in indolent chronic lymphocytic leukemia","volume":"338","author":"Dighiero","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2007.08.003_bib30","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/jnci\/91.10.861","article-title":"Chemotherapeutic options in chronic lymphocytic leukaemia: a meta-analysis of the randomized trials","volume":"91","author":"CLL Trialsts Collaborative Group","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2007.08.003_bib31","first-page":"1357","article-title":"Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I\/II study of the German CLL Study Group","volume":"90","author":"Bergmann","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2007.08.003_bib32","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1568009054863618","article-title":"Purine nucleoside analogues for the treatment of haematological malignancies: pharmacology and clinical applications","volume":"5","author":"Robak","year":"2005","journal-title":"Curr Cancer Drug Target"},{"key":"10.1016\/j.ctrv.2007.08.003_bib33","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/10428190290012029","article-title":"The role of nucleoside analogues in the treatment of chronic lymphocytic leukemia: lessons learned from prospective randomized trials","volume":"43","author":"Robak","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2007.08.003_bib34","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood.V86.7.2463.2463","article-title":"Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders","volume":"86","author":"Tallman","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib35","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1053\/beha.2002.0211","article-title":"Non-Hodgkin\u2019s lymphoma: the evolving role of purine analogues","volume":"15","author":"Zinzani","year":"2002","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib36","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ctrv.2006.04.010","article-title":"Current treatment options in hairy cell leukemia and hairy cell leukemia variant","volume":"32","author":"Robak","year":"2006","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2007.08.003_bib37","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2007.08.003_bib38","first-page":"2723","article-title":"Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial","volume":"96","author":"Robak","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib39","first-page":"171","article-title":"Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1)","volume":"11","author":"Robak","year":"2005","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.ctrv.2007.08.003_bib40","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(96)91681-5","article-title":"Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin and prednisone (CAP) for treatment of advanced stage chronic lymphocytic leukemia. The French Cooperative Group on CLL","volume":"347","author":"Johnson","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2007.08.003_bib41","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V98.8.2319","article-title":"French Cooperative Group on Chronic Lymphocytic Leukemia. Randomized comparison of fludarabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients","volume":"98","author":"Leporrier","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib42","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood.V81.11.2878.2878","article-title":"Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent","volume":"81","author":"Keating","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib43","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ctrv.2006.05.002","article-title":"Single agent purine analogues for the treatment of chronic lymphocytic leukemia: a systematic review and meta analysis","volume":"32","author":"Steurer","year":"2006","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2007.08.003_bib44","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1046\/j.1365-2141.2000.01850.x","article-title":"Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukemia- updated results of the multicentre study of 378 patients","volume":"108","author":"Robak","year":"2000","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib45","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V92.4.1165","article-title":"Long term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regiments as initial therapy","volume":"92","author":"Keating","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib46","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood.V72.3.1069.bloodjournal7231069","article-title":"2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia","volume":"71","author":"Piro","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib47","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1586\/14737140.4.1.27","article-title":"Pentostatin (Nipent) in the treatment of chronic lymphocyte leukemia and hairy cell leukemia","volume":"4","author":"Dillman","year":"2004","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ctrv.2007.08.003_bib48","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580","article-title":"P53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias","volume":"85","author":"Dohner","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib49","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1182\/blood-2003-09-3236","article-title":"Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53 dependent gene expression response","volume":"104","author":"Rosenwald","year":"2004","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2007.08.003_bib50","first-page":"945a","article-title":"Cladribine (CdA) or fludarabine (F) or high-dose intermittent chlorambucil (Chl) as first-line treatment of symptomatic chronic lymphocytic leukemia: first interim analysis of data from the international randomized phase III trial","volume":"104","author":"Karlsson","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib51","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1056\/NEJM199210083271504","article-title":"Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine","volume":"327","author":"Juliusson","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2007.08.003_bib52","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/sj.leu.2402752","article-title":"A phase II study of cladribine treatment for fludarabine refractory chronic lymphocytic leukemia: results from CALGB Study 9211","volume":"17","author":"Byrd","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2007.08.003_bib53","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJM199402033300504","article-title":"Lack of effects of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy","volume":"330","author":"Brien","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2007.08.003_bib54","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1200\/JCO.2004.05.012","article-title":"Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia","volume":"22","author":"Rossi","year":"2004","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2007.08.003_bib55","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1038\/sj.thj.6200389","article-title":"Oral fludarabine therapy in chronic lymphocytic leukemia-increased convenience","volume":"5","author":"Boogaerts","year":"2004","journal-title":"Hematology"},{"key":"10.1016\/j.ctrv.2007.08.003_bib56","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1200\/JCO.1996.14.7.2160","article-title":"Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia","volume":"14","author":"Juliusson","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib57","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1046\/j.0007-1048.2001.03296.x","article-title":"Oral cladribine for B-cell chronic lymphocytic leukemia report of a phase II trial with a 3-d, 3 weekly schedule in untreated and pretreated patients and a long-term follow up of 126 previously treated patients","volume":"116","author":"Karlsson","year":"2002","journal-title":"Brit J Hematol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib58","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1200\/JCO.2001.19.5.1414","article-title":"Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia","volume":"19","author":"O\u2019Brien","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib59","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1046\/j.1365-2141.2001.02959.x","article-title":"Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group","volume":"14","author":"Hallek","year":"2001","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib60","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":"Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia","volume":"107","author":"Eichhorst","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib61","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","article-title":"Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997","volume":"25","author":"Flinn","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib62","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 Trial): a randomized controlled trial","volume":"370","author":"Catovsky","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2007.08.003_bib63","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/cncr.11000","article-title":"Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia","volume":"97","author":"Montillo","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2007.08.003_bib64","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/sj.thj.6200191","article-title":"Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia","volume":"3","author":"Robak","year":"2002","journal-title":"Hematol J"},{"key":"10.1016\/j.ctrv.2007.08.003_bib65","doi-asserted-by":"crossref","first-page":"800a","DOI":"10.1182\/blood-2005-12-4828","article-title":"Randomized comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphaide in progressive chronic lymphocytic leukemia: an updated report of prospective PALG \u2013 CLL3 study","volume":"108","author":"Robak","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib66","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1200\/JCO.2003.08.100","article-title":"Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia","volume":"21","author":"Weiss","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib67","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1002\/cncr.20264","article-title":"Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia","volume":"100","author":"Tsimberidou","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2007.08.003_bib68","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1046\/j.1365-2141.2002.03959.x","article-title":"Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukemia","volume":"119","author":"Bosch","year":"2002","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib69","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1034\/j.1600-0609.2001.00303.x","article-title":"Cladribine in combination with mitoxantrone and cyclophosphamide (CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies","volume":"66","author":"Robak","year":"2001","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib70","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1038\/sj.leu.2402216","article-title":"Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia","volume":"15","author":"Robak","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2007.08.003_bib71","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2005-12-4828","article-title":"Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2)","volume":"108","author":"Robak","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib72","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/1042819031000139666","article-title":"Monoclonal antibodies in the treatment of chronic lymphoid leukemias","volume":"45","author":"Robak","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2007.08.003_bib73","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1586\/14737140.6.12.1787","article-title":"Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia","volume":"6","author":"Del Poeta","year":"2006","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ctrv.2007.08.003_bib74","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/00003495-199958010-00009","article-title":"Rituximab","volume":"58","author":"Onrust","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.ctrv.2007.08.003_bib75","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/00001622-200011000-00010","article-title":"Campath-II monoclonal antibody therapy","volume":"12","author":"Flynn","year":"2000","journal-title":"Curr Opin Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.ctrv.2007.08.003_bib76","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/sonc.2002.30142","article-title":"Emerging information on the use of rituximab in chronic lymphocytic leukemia","volume":"29","author":"Keating","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib77","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3816\/CLM.2000.n.015","article-title":"Rituximab therapy of B-cell neoplasms","volume":"1","author":"Petryk","year":"2000","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.ctrv.2007.08.003_bib78","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2002-06-1639","article-title":"Cirxulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and its prognostic significance","volume":"101","author":"Manshouri","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib79","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","article-title":"Rituximab dose-escalation trial in chronic lymphocytic leukemia","volume":"19","author":"O\u2019Brien","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib80","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","article-title":"Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity","volume":"19","author":"Byrd","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib81","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s002779900141","article-title":"Successful treatment and re-treatment of resistant B-cell chronic lymphocytic leukemia with the monoclonal anti-CD20 antibody rituximab","volume":"79","author":"Herold","year":"2000","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib82","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1034\/j.1600-0609.2002.02786.x","article-title":"Standard dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukemia: results from a Nordic multicentre study","volume":"129","author":"Itala","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib83","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/00063030-200519010-00002","article-title":"Alemtuzumab in the treatment of chronic lymphocytic leukemia","volume":"9","author":"Robak","year":"2005","journal-title":"Biodrugs"},{"key":"10.1016\/j.ctrv.2007.08.003_bib84","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","article-title":"Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia","volume":"15","author":"Osterborg","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib85","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib86","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/cncr.11551","article-title":"Phase II study of alemtuzumab in chronic lymphoproliferative disorders","volume":"98","author":"Ferrajoli","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2007.08.003_bib87","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2003-10-3729","article-title":"Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and delection","volume":"103","author":"Lozanski","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib88","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1182\/blood-2002-07-1952","article-title":"Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies","volume":"101","author":"Faderl","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib89","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood-2002-10-3270","article-title":"Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia","volume":"103","author":"Rawstron","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib90","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1080\/10428190290021597","article-title":"Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukaemia","volume":"43","author":"McCune","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2007.08.003_bib91","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/blood.V99.6.2245","article-title":"Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia","volume":"99","author":"Kennedy","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib92","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJM200208083470619","article-title":"Campath-1H: induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy","volume":"347","author":"Stilgenbauer","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2007.08.003_bib93","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2141.1996.450989.x","article-title":"Humanized CD52 monoclonal antibody Campath-1H as first line treatment in chronic lymphocytic leukemia","volume":"93","author":"Osterborg","year":"1996","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib94","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood-2002-01-0159","article-title":"Phase II trial of subcutaneous anti CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)","volume":"100","author":"Lundin","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib95","doi-asserted-by":"crossref","unstructured":"Hillmen P, Skotnicki A, Robak T, et al. Alemtuzumab compared with chlorambucil as first line therapy for patients requiring treatment for chronic lymphocytic leukemia. J Clin Oncol 2007 [in press].","DOI":"10.1200\/JCO.2007.12.9098"},{"key":"10.1016\/j.ctrv.2007.08.003_bib96","doi-asserted-by":"crossref","first-page":"592a","DOI":"10.1182\/blood.V108.11.2092.2092","article-title":"Incidence of genomic aberrations and associated efficacy from a phase III study comparing alemtuzumab (CAMPATH MABCAMPATH) vs. chlorambucil as first line therapy for B-cell chronic lymphocytic leukemia (BCLL)","volume":"108","author":"Robak","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib97","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3816\/CLM.2004.n.002","article-title":"Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia","volume":"4","author":"Keating","year":"2004","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.ctrv.2007.08.003_bib98","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1200\/JCO.2005.05.008","article-title":"Novel immune-based treatment strategies for chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib99","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/13693780400007151","article-title":"Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells","volume":"46","author":"Smolewski","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2007.08.003_bib100","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2002-03-0972","article-title":"Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia","volume":"100","author":"Schulz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib101","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1002\/cncr.21535","article-title":"The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70 negative chronic lymphocytic leukemia","volume":"104","author":"Del Poeta","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2007.08.003_bib102","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent vs. sequential treatment with rituximab in symptomatic untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALG B9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib103","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib104","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for relapsed and refractory chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib105","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2004-03-0796","article-title":"Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective analysis of CALGB 9712 and CALGB 9011","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib106","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.2005.04.3836","article-title":"Pentostatin, cyclophosphamide, and rituximab is an active, well tolerated regimen for patients with previously treated chronic lymphocytic leukemia","volume":"24","author":"Lamanna","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib107","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2006-07-033274","article-title":"Combination chemoimmunotherapy with pentostatin, cyclophosphamide and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia","volume":"109","author":"Kay","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib108","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1600-0609.2007.00889.x","article-title":"Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"79","author":"Robak","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib109","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/cncr.22196","article-title":"Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma","volume":"107","author":"Robak","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2007.08.003_bib110","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.beha.2006.06.005","article-title":"Monoclonal antibody combinations in CLL: evolving strategies","volume":"19","author":"Faderl","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib111","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1200\/JCO.2005.01.9950","article-title":"Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial","volume":"23","author":"Elter","year":"2005","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2007.08.003_bib112","first-page":"205a","article-title":"A phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease. Cancer and Leukemia Group B (CALGB) Study 199","volume":"100","author":"Rai","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib113","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1200\/JCO.2005.04.6037","article-title":"Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia","volume":"24","author":"Montillo","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib114","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/sj.leu.2403354","article-title":"Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission: experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL. Study Group (GCLLSG)","volume":"18","author":"Wendtner","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2007.08.003_bib115","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s11864-006-0013-x","article-title":"New agents in chronic lymphocytic leukemia","volume":"7","author":"Robak","year":"2006","journal-title":"Curr Treat Opt Oncol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib116","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0268-960X(03)00039-0","article-title":"Novel therapies for chronic lymphocytic leukemia","volume":"18","author":"Mavromatis","year":"2004","journal-title":"Blood Rev"},{"key":"10.1016\/j.ctrv.2007.08.003_bib117","doi-asserted-by":"crossref","first-page":"290b","DOI":"10.1182\/blood.V104.11.4831.4831","article-title":"Pharmacokinetics of single-agent lumiliximab (anti-CD23 antibody) in patients with chronic lymphocytic leukemia","volume":"104","author":"Woodworth","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib118","doi-asserted-by":"crossref","first-page":"805a","DOI":"10.1182\/blood.V108.11.2842.2842","article-title":"Significant correlation between survival and points and exposure to ofatumumab (HuMax-CD20) in chronic lymphocytic leukemia","volume":"108","author":"Coiffier","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib119","doi-asserted-by":"crossref","first-page":"7697","DOI":"10.1200\/JCO.2005.02.4364","article-title":"Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide in patients with advanced chronic lymphocytic leukemia","volume":"23","author":"O\u2019Brien","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib120","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.2006.07.1191","article-title":"Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"20","author":"O\u2019Brien","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib121","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.leukres.2005.03.010","article-title":"Flavopirydol administered as a 24 hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity","volume":"28","author":"Flinn","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.ctrv.2007.08.003_bib122","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1158\/1078-0432.CCR-04-2276","article-title":"Treatment of relapsed chronic lymphocytic leukemia by 72 hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805","volume":"11","author":"Byrd","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2007.08.003_bib123","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2006-05-020735","article-title":"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia","volume":"109","author":"Byrd","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib124","first-page":"113","article-title":"Factors affecting bryostatin 1-enhanced 2-CdA cytotoxicity in resistant B-cell chronic lymphocytic leukemia","volume":"14","author":"Beck","year":"2004","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.ctrv.2007.08.003_bib125","first-page":"445","article-title":"Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies","author":"Mohammad","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2007.08.003_bib126","first-page":"1328","article-title":"Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report","volume":"66","author":"Ahmad","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2007.08.003_bib127","doi-asserted-by":"crossref","first-page":"5809","DOI":"10.1158\/1078-0432.CCR-05-2730","article-title":"Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin\u2019s) lymphoma","volume":"12","author":"Roberts","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2007.08.003_bib128","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1182\/blood-2005-02-0669","article-title":"Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL)","volume":"106","author":"Chanan-Khan","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib129","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.leukres.2006.05.013","article-title":"Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pretreated patients with chronic lymphocytic leukemia","volume":"31","author":"Laurenti","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.ctrv.2007.08.003_bib130","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1200\/JCO.2005.05.0401","article-title":"Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study","volume":"24","author":"Chanan-Khan","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib131","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bbmt.2007.01.075","article-title":"Hematopoietic cell transplantation for chronic lymphocytic leukemia: an evolving concept","volume":"13","author":"Kharfan-Dabaja","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ctrv.2007.08.003_bib132","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1182\/asheducation-2005.1.292","article-title":"Salvage therapy for CLL and the role of stem cell transplantation. Hematology","author":"Gribben","year":"2005","journal-title":"Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ctrv.2007.08.003_bib133","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1182\/blood-2005-05-1778","article-title":"Autologous and allogenic stem cell transplantations for poor-risk chronic lymphocytic leukemia","volume":"106","author":"Gribben","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib134","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1182\/blood-2003-05-1549","article-title":"The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk matched analysis based on the VH gene mutational status","volume":"103","author":"Dreger","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib135","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2141.2004.05250.x","article-title":"Stem cell transplantation for chronic lymphocytic leukemia","volume":"128","author":"Paneesha","year":"2004","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib136","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1182\/blood-2002-06-1744","article-title":"Unmutated immunoglobulin variable heavy chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia","volume":"101","author":"Ritgen","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib137","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2004-01-0298","article-title":"Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular response","volume":"105","author":"Milligan","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib138","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7326\/0003-4819-124-3-199602010-00005","article-title":"HLA identical sibling bone marrow transplants for chronic lymphocytic leukemia","volume":"124","author":"Michallet","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ctrv.2007.08.003_bib139","first-page":"474a","article-title":"Conventional HLA-identical sibling bone marrow transplantation is able to cure chronic lymphocytic leukemia","volume":"102","author":"Michallet","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib140","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/sj.bmt.1702237","article-title":"Outcome of allogenic stem cell transplantation for B-cell chronic lymphocytic leukemia","volume":"25","author":"Pavletic","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ctrv.2007.08.003_bib141","doi-asserted-by":"crossref","first-page":"5788","DOI":"10.1200\/JCO.2005.03.962","article-title":"Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning results from the center for international blood and marrow transplant research","volume":"23","author":"Pavletic","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib142","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/sj.leu.2403745","article-title":"Reduced intensity conditioning lowers treatment related mortality of allogenic stem cell transplantation for chronic lymphocytic leukemia: a population matched analysis","volume":"19","author":"Dreger","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2007.08.003_bib143","first-page":"1724","article-title":"Treatment related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity reduced conditioning","volume":"107","author":"Dreger","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2007.08.003_bib144","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2005-08-3372","article-title":"Results of alemtuzumab-based reduced intensity allogenic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study","volume":"107","author":"Delgado","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.08.003_bib145","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1200\/JCO.2003.12.011","article-title":"Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced intensity conditioning and allogenic stem cell transplantation: the Cooperative German Transplant Study Group","volume":"21","author":"Schetelig","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib146","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1200\/JCO.2005.04.569","article-title":"Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia","volume":"23","author":"Sorror","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.08.003_bib147","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.leu.2404441","article-title":"Indication for allogenic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus","volume":"21","author":"Dreger","year":"2007","journal-title":"Leukemia"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737207001181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737207001181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:19:14Z","timestamp":1587946754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737207001181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":147,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S0305737207001181"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2007.08.003","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}